This month, we want to share the acknowledgment that APICES has received in the recent publication titled “A phase 2 study for evaluating doxycycline 50 mg once daily and 100 mg once daily as preemptive treatment for skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy” published in Supportive Care in Cancer in which APICES has collaborated in several tasks of the project as design, setup, coordination and project management, data management, statistical analysis and preparation of the manuscript. This means an extra motivation to all APICES team in order to give continuity to the implication we have in every project in which we collaborate. APICES is very proud of the recognition of our work, and we would like to thank Fundación CRIS and Dr Ramírez Daffos for giving us the opportunity to appear in the acknowledgements of the publication and congratulate them and all the investigators for their project success.
This study was designed to assess the efficacy, safety, and quality of life outcomes of doxycycline 50 or 100 mg once daily in the prevention of skin toxicity in patients undergoing chemotherapy plus anti-EGFR therapy as first-line treatment of metastatic colorectal cancer (mCRC).
You can find the publication in the following link:
https://link.springer.com/article/10.1007/s00520-022-07254-5
